Sino Biopharmaceutical (OTCMKTS:SBMFF) Sees Large Drop in Short Interest

Key Points

• Sino Biopharmaceutical experienced a significant decrease in short interest, dropping 30.6% from August to a total of 34,229,400 shares as of mid-September.
• The stock's current trading price stands at $1.07, with a 52-week range between $0.37 and $1.24.
• Sino Biopharmaceutical operates as a pharmaceutical conglomerate in China, focusing on oncology, liver disease, and respiratory medications.

Sino Biopharmaceutical (OTCMKTS:SBMFF - ) was the recipient of a large decline in short interest in the month of September. As of September 15th, there was short interest totaling 34,229,400 shares, a decline of 30.6% from the August 31st total of 49,345,500 shares. Based on an average daily trading volume, of 900 shares, the days-to-cover ratio is presently 38,032.7 days. Based on an average daily trading volume, of 900 shares, the days-to-cover ratio is presently 38,032.7 days.

Sino Biopharmaceutical Price Performance

Shares of SBMFF stock traded down $0.02 on Monday, hitting $1.07. The stock had a trading volume of 3,000 shares, compared to its average volume of 2,715. Sino Biopharmaceutical has a 1 year low of $0.37 and a 1 year high of $1.24. The company's 50 day moving average price is $1.04 and its 200-day moving average price is $0.74.

Sino Biopharmaceutical Company Profile

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.